OSE Immunotherapeutics SA

OSE Immunotherapeutics SA is a clinical-stage biotechnology company headquartered in Nantes, France, dedicated to developing and partnering first-in-class immunotherapies. The company's core mission revolves around controlling the immune system to address significant unmet medical needs in immuno-oncology and immuno-inflammation.

OSE Immunotherapeutics boasts a diversified clinical pipeline featuring several key product candidates. These include Tedopi®, a T-cell-based cancer vaccine, OSE-279, an anti-PD1 antibody, and Lusvertikimab (OSE-127), a humanized monoclonal antibody targeting the IL-7 receptor. The pipeline also comprises partnered assets such as FR-104/VEL-101 (anti-CD28 mAb), BI 765063/BI 770371 (anti-SIRPα mAb), and OSE-230 (ChemR23 agonist mAb). The company leverages proprietary drug discovery platforms, including Pro-resolutive mAb, Myeloid Checkpoint, and BiCKI® systems, to drive its research and development efforts in immuno-oncology and autoimmune diseases.

Recent developments highlight OSE Immunotherapeutics' strategic focus and advancements. In March 2026, Marc Le Bozec was confirmed as the Chief Executive Officer, with Thomas Gidoin appointed Deputy CEO and Aurore Morello as Chief Scientific Officer in April 2026, strengthening the leadership team. The company received an FDA Orphan Drug Designation for pegrizeprument (VEL-101), developed in partnership with Veloxis Pharmaceuticals, in April 2026, for anti-rejection treatment. Tedopi® was also selected for presentation at the ASCO 2026 meeting. OSE Immunotherapeutics has established strategic partnerships with major pharmaceutical companies like AbbVie and Boehringer Ingelheim, contributing to its market positioning as an innovative player in the immunotherapy landscape.